PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Phase 3
Recruiting
- Conditions
- Alopecia Areata
- Interventions
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 550
- Registration Number
- NCT06873945
- Locations
- 🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸Southern California Clinical Research, Santa Ana, California, United States
🇺🇸Brett King MD, LLC, Fairfield, Connecticut, United States
A Study to Learn More About Tukysa Once it is Out in the Korean Market
Not yet recruiting
- Conditions
- HER2-positive Locally Advanced UnresectableMetastatic Breast Cancer
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT06873191
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.
Phase 1
Recruiting
- Conditions
- Peripheral T Cell LymphomaDiffuse Large B-cell LymphomaClassical Hodgkin LymphomaHead and Neck Squamous Cell CarcinomaMelanomaNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT06870487
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center., Seattle, Washington, United States
🇺🇸University of Washington Medical Center- Montlake, Seattle, Washington, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 550
- Registration Number
- NCT06866405
- Locations
- 🇺🇸
Emerald Coast Pediatrics, Panama City, Florida, United States
🇺🇸Emerald Coast OBGYN Clinical Research, Panama City, Florida, United States
🇺🇸HCA Florida Gulf Coast Hospital, Panama City, Florida, United States
A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
Not yet recruiting
- Conditions
- Infectious Diseases
- Interventions
- Drug: Avibactam sodium/Ceftazidime hydrate
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT06864585
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Phase 1
Active, not recruiting
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT06837259
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Biological: Placebo for PF-07314470
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 103
- Registration Number
- NCT06821750
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
Active, not recruiting
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Biological: ABRYSVO Vaccination
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06813872
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT06807268
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT06807281
© Copyright 2025. All Rights Reserved by MedPath